HIV-1 drug resistance in recently HIV-infected pregnant mother's naïve to antiretroviral therapy in Dodoma urban, Tanzania

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Vairo, Francesco ^a   Nicastri, Emanuele ^a   Liuzzi, Giuseppina ^a   Chaula, Zainab ^b   Nguhuni, Boniface ^b   Bevilacqua, Nazario ^a   Forbici, Federica ^a   Amendola, Alessandra ^a   Fabeni, Lavinia ^a   De Nardo, Pasquale ^a   Perno, Carlo F ^a   Cannas, Angela ^a   Sakhoo, Calistus ^b   Capobianchi, Maria R ^a   Ippolito, Giuseppe ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b Dodoma Regional Hospital   (Tanzania)

Author keywords

HIV drug resistance; HIV genotype; Low resources countries; MTCT

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GESTATIONAL AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PREGNANT WOMAN; TANZANIA; URBAN POPULATION; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN; CLASSIFICATION; DISEASE TRANSMISSION; DRUG EFFECT; GENETICS; HEALTH; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; MOTHER; PHYLOGENY; PREGNANCY; PREGNANCY COMPLICATION; VIROLOGY; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MOTHERS; PHYLOGENY; PREGNANCY; PREGNANCY COMPLICATIONS; TANZANIA; URBAN HEALTH; YOUNG ADULT;

EID: 84884304275     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-439     Document Type: Article

References (22)

1. Global HIV/AIDS response: epidemic update and health sector progress towards universal access: progress report 2011 2011, Geneva: WHO.
2. Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, Clarke J, Churchill D, Williams I, Hill T, Green H, Porter K, Scullard G, Johnson M, Easterbrook P, Gilson R, Fisher M, Loveday C, Gazzard B, Pillay D, UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group Long-term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005, 19:487-494. UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group.
3. Geretti AM, Harrison L, Green H, Sabin C, Hill T, Fearnhill E, Pillay D, Dunn D, UK Collaborative Group on HIV Drug Resistance Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis 2009, 48:1296-1305. 10.1086/598502, 19331585, UK Collaborative Group on HIV Drug Resistance.
4. Marcelin AG, Masquelier B, Descamps D, Izopet J, Charpentier C, Alloui C, Bouvier-Alias M, Signori-Schmuck A, Montes B, Chaix ML, Amiel C, Santos GD, Ruffault A, Barin F, Peytavin G, Lavignon M, Flandre P, Calvez V. Tipranavir ritonavir genotypic resistance score in protease inhibitor experienced patients. Antimicrob Agents Chemother 2008, 52:3237-3243. 10.1128/AAC.00133-08, 2533483, 18625773.
5. Miller MD, Margot N, McColl D, Cheng AK. K65R development among subtype C HIV-1 patient's in tenofovir DF clinical trials. AIDS 2007, 21:265-266. 10.1097/QAD.0b013e32801199ee, 17197831.
6. Flys TS, Chen S, Jones DC, Hoover DR, Church JD, Fiscus SA, Mwatha A, Guay LA, Mmiro F, Musoke P, Kumwenda N, Taha TE, Jackson JB, Eshleman SH. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J Acquir Immune Defic Syndr 2006, 42:610-613. 10.1097/01.qai.0000221686.67810.20, 16773030.
7. Deshpande A, Jauvin V, Magnin N, Pinson P, Faure M, Masquelier B, Aurillac-Lavignolle V, Fleury HJ. Resistance mutations in subtype C HIV type 1 isolates from Indian patients of Mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure: resistance to AR. AIDS Res Hum Retroviruses 2007, 23:335-340. 10.1089/aid.2006.0183, 17331042.
8. Grossman Z, Istomin V, Averbuch D, Lorber M, Risenberg K, Levi I, Chowers M, Burke M, Bar Yaacov N, Schapiro JM, Israel AIDS Multi-Center Study Group Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS 2004, 18:909-915. 10.1097/00002030-200404090-00008, 15060438, Israel AIDS Multi-Center Study Group.
9. Perno CF, Cozzi-Lepri A, Balotta C, Forbici F, Violin M, Bertoli A, Facchi G, Pezzotti P, Cadeo G, Tositti G, Pasquinucci S, Pauluzzi S, Scalzini A, Salassa B, Vincenti A, Phillips AN, Dianzani F, Appice A, Angarano G, Monno L, Ippolito G, Moroni M, d' Arminio Monforte A, Italian Cohort Naive Antiretroviral (I.CO.N.A.) Study Group Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis 2001, 184:983-991. 10.1086/323604, 11574912, Italian Cohort Naive Antiretroviral (I.CO.N.A.) Study Group.
10. Ceccherini-Silberstein F, Erba F, Gago F, Bertoli A, Forbici F, Bellocchi MC, Gori C, D'Arrigo R, Marcon L, Balotta C, Antinori A, Monforte AD, Perno CF. Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure. AIDS 2004, 18:F11-F19.
11. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, Heneine W, Kantor R, Jordan MR, Schapiro JM, Vandamme AM, Sandstrom P, Boucher CA, van de Vijver D, Rhee SY, Liu TF, Pillay D, Shafer RW. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009, 4:e4724. 10.1371/journal.pone.0004724, 2648874, 19266092.
12. The HIV drug resistance report - 2012 WHO 2013, Geneva, last access July 12, 2013 on http://apps.who.int/iris/bitstream/10665/75183/1/9789241503938_eng.pdf.
13. Nyombi BM, Holm-Hansen C, Kristiansen KI, Bjune G, Müller F. Prevalence of reverse transcriptase and protease mutations associated with antiretroviral drug resistance among drug-naïve HIV-1 infected pregnant women in Kagera and Kilimanjaro regions, Tanzania. AIDS Res Ther 2008, 21:13.
14. Mosha F, Urassa W, Aboud S, Lyamuya E, Sandstrom E, Bredell H, Williamson C. Prevalence of genotypic resistance to antiretroviral drugs in treatment-naive youths infected with diverse HIV type 1 subtypes and recombinant forms in Dar es salaam, Tanzania. AIDS Res Human Retovir 2011, 27:377-380.
15. Kasang C, Kalluvya S, Majinge C, Stich A, Bodem J, Kongola G, Jacobs GB, Mlewa M, Mildner M, Hensel I, Horn A, Preiser W, van Zyl G, Klinker H, Koutsilieri E, Rethwilm A, Scheller C, Weissbrich B. HIV drug resistance (HIVDR) in antiretroviral therapy-naïve patients in Tanzania not eligible for WHO threshold HIVDR survey is dramatically high. PLoS One 2011, 6:e23091. 10.1371/journal.pone.0023091, 3158766, 21886779.
16. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, Botes ME, Wellington M, Osibogun A, Sigaloff KC, Nankya I, Schuurman R, Wit FW, Stevens WS, van Vugt M, de Wit TF, PharmAccess African Studies to Evaluate Resistance (PASER) HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011, 11:750-759. 10.1016/S1473-3099(11)70149-9, 21802367, PharmAccess African Studies to Evaluate Resistance (PASER).
17. Velazquez-Campoy A, Todd MJ, Vega S, Freire E. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci USA 2001, 98:6062-6067. 10.1073/pnas.111152698, 33422, 11353856.
18. Calazans A, Brindeiro R, Brindeiro P, Verli H, Arruda MB, Gonzalez LM, Guimaraes JA, Diaz RS, Antunes OA, Tanuri A. Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism. J Infect Dis 2005, 191:1170-1961.
19. Santoro MM, Alteri C, Ronga L, Flandre P, Fabeni L, Mercurio F, D'Arrigo R, Gori C, Palamara G, Bertoli A, Forbici F, Salpini R, Boumis E, Tozzi V, Visco-Comandini U, Zaccarelli M, Van Houtte M, Pattery T, Narciso P, Antinori A, Ceccherini-Silberstein F, Perno CF. Comparative analysis of drug resistance among B and the most prevalent Non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy. AIDS Res Hum Retroviruses 2012, 28:1285-1293. 10.1089/aid.2011.0142, 22417570.
20. Richard N, Juntilla M, Abraha A, Demers K, Paxinos E, Galovich J, Petropoulos C, Whalen CC, Kyeyune F, Atwine D, Kityo C, Mugyenyi P, Arts EJ. High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2004, 20:355-364. 10.1089/088922204323048104, 15157354.
21. Schouten EJ, Jahn A, Midiani D, Makombe SD, Mnthambala A, Chirwa Z, Harries AD, van Oosterhout JJ, Meguid T, Ben-Smith A, Zachariah R, Lynen L, Zolfo M, Van Damme W, Gilks CF, Atun R, Shawa M, Chimbwandira F. Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet 2011, 378:282-284. 10.1016/S0140-6736(10)62303-3, 21763940.
22. WHO programmatic update. Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants 2012, Accessible though: http://www.who.int/hiv/PMTCT_update.pdf.